JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $3,885,000 | -3.8% | 85,000 | -5.6% | 1.36% | -17.1% |
Q3 2017 | $4,037,000 | -17.3% | 90,000 | -1.7% | 1.64% | -4.6% |
Q2 2015 | $4,884,000 | -12.1% | 91,575 | 0.0% | 1.71% | -47.9% |
Q1 2015 | $5,555,000 | +16.2% | 91,575 | 0.0% | 3.29% | +0.5% |
Q4 2014 | $4,782,000 | – | 91,575 | – | 3.27% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |